Search results for "promises and pitfalls of pharmacogenetic approache"

showing 1 items of 1 documents

Pharmacogenetics of treatments for pancreatic cancer

2019

Introduction: Despite clinical efforts, pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The scarcity of effective therapies can be reflected by the lack of reliable biomarkers to adapt anticancer drugs prescription to tumors’ and patients’ features. Areas covered: Pharmacogenetics should provide the way to select patients who may benefit from a specific therapy that best matches individual and tumor genetic profile, but it has not yet led to gains in outcome. This review describes PDAC pharmacogenetics findings, critically reappraising studies on polymorphisms and -omics profiles correlated to response to gemcitabine, FOLFIRINOX, and nab-paclitaxel combinations, as well as l…

Oncologymedicine.medical_specialtyPancreatic ductal adenocarcinomaendocrine system diseasesFOLFIRINOXToxicology030226 pharmacology & pharmacyvalidated tests and clinical trial03 medical and health sciencesnab-paclitaxel0302 clinical medicinePancreatic cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorAnimalsHumansneoplasmspharmacogenetic studieNab-paclitaxelPharmacologyAntineoplastic Combined Chemotherapy Protocolbusiness.industryAnimalPatient SelectionPharmacogeneticfungigemcitabinePancreatic Neoplasmfood and beveragesGeneral MedicinePancreatic cancermedicine.diseasePrognosisSettore CHIM/08 - Chimica Farmaceuticadigestive system diseasesGemcitabinePancreatic NeoplasmsFOLFIRINOXPharmacogenetics030220 oncology & carcinogenesispromises and pitfalls of pharmacogenetic approachebusinessPharmacogeneticsmedicine.drugCarcinoma Pancreatic DuctalHumanExpert Opinion on Drug Metabolism and Toxicology
researchProduct